Recent Updates — MRK

Merck & Co., Inc. reported third-quarter 2026 GAAP earnings per share of $2.04 and non-GAAP EPS of $2.49, both including a one-time charge of $0.12 per share related to a global license agreement with SciBrunch. Worldwide sales reached $18.1 billion, reflecting 5% growth driven by KEYTRUDA ($8.6 billion) and WINREVAIR ($694 million). The company narrowed and raised its full-year 2026 sales outlook to between $66.8 billion and $67.3 billion, while raising the expected non-GAAP EPS range to $2.77-$2.82. Merck operates as a research-intensive biopharmaceutical company developing medicines and vaccines.

Merck & Co., Inc. announced the election of Paul J. Diaz to its Board of Directors, effective November 1, 2026. Diaz, currently managing partner at Cressey & Company and former CEO of Myriad Genetics and Kindred Healthcare, will serve on the Audit and Research Committees. He will stand for shareholder election in May 2027, bringing healthcare industry expertise to the board which now consists of 14 members. Merck is a research-intensive biopharmaceutical company that develops medicines and vaccines.

Merck & Co., Inc. reported second-quarter 2026 results on August 4, 2026, reporting a GAAP loss per share of $0.54 and non-GAAP loss per share of $0.13, driven by a $2.31 per share charge for the acquisition of Terns Pharmaceuticals. Total worldwide sales reached $16.6 billion, representing 5% growth year-over-year, with KEYTRUDA/KEYTRUDA QLEX sales contributing $8.4 billion and WINREVAIR sales surging 75% to $588 million. The company narrowed and raised its full-year 2026 sales outlook to between $66.3 billion and $67.3 billion, while raising the expected non-GAAP EPS range to between $2.66 and $2.76. Merck operates in the pharmaceutical industry, developing and commercializing medicines, vaccines, and animal health products.